11421 Saskatchewan Drive Edmonton, AB, Canada T6G2M9 email@example.com
KMT Hepatech, Inc. provides efficient and cost-effective in vivo research services utilizing our proprietary platform technology of small animal model, the KMT MouseTM.
The KMT MouseTM is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of up to 95 per cent.
We are proud to acknowledge that generated in KMT MouseTM drug therapy responses parallel those seen in humans during clinical trials.
KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.
Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas:
November 17 2014
Efficacy studies with Tenofovir and Entecavir and updated information on HBV in vivo services
July 28 2014
Dr. Houghton leads hepatitis C (HCV) vaccine development at the University of Alberta
June 03 2014
Nature Publishing Group's Biopharma Dealmakers features Mouse model with humanized liver